Hippokratia 2011; 15(Suppl 1): 53-68
G. Tsagalis
Category: Volume 15 (2011) – Supplement 1
The effect of the expenditure increase in the morbidity and the mortality of patients with end stage renal disease: the USA case
Hippokratia 2011; 15 (Suppl 1): 16-21
A. Letsios
Secondary hyperparathyroidism and target organs in chronic kidney disease
Hippokratia 2011; 15 (Suppl 1): 33-38
M. Nikodimopoulou, S. Liakos
Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study results
Hippokratia 2011; 15 (Suppl 1): 27-32
M. Baltatzi, Ch. Savopoulos, A. Hatzitolios
Renal anemia: a nephrologist’s view
Hippokratia 2011; 15(Suppl 1): 39-43
G. Tsagalis
Pregnancy in women with renal disease. Yes or no?
Hippokratia 2011; 15 (Suppl 1): 8-12
K. Edipidis
Phosphorus metabolism in chronic kidney disease
Hippokratia 2011; 15 (Suppl 1): 50-52
C. Fourtounas
Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure
Hippokratia 2011; 15 (Suppl 1): 22-26
S. Spaia
Is the underutilization of peritoneal dialysis in relation to hemodialysis, as renal replacement therapy, justifiable worldwide? Yes or No
Hippokratia 2011; 15 (Suppl 1): 13-15
E. Grapsa
Is the dietary protein restriction achievable in chronic kidney disease? The impact upon quality of life and the dialysis delay
Hippokratia 2011; 15 (Suppl 1): 3-7
E. Koulouridis, I. Koulouridis
Are we satisfied with the follow-up of hypertensive and chronic kidney disease patients in outpatient clinics?
Hippokratia 2011; 15(Suppl 1): 44-49
M. Peppa, D. Vlahakos